OnKure Therapeutics (OKUR) Stock Price, News & Analysis

Company Overview

OnKure Therapeutics, Inc. (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for fibrotic diseases and oncology. The company leverages an integrated, data-driven platform that combines target identification, machine learning and functional screening to accelerate the selection of small molecules and biologics with the potential to reverse fibrosis or modulate the tumor microenvironment. OnKure’s approach is designed to address high-unmet-need diseases where current treatment options are limited.

OnKure’s pipeline includes ONK-002, a first-in-class small molecule targeting key drivers of liver fibrosis in nonalcoholic steatohepatitis (NASH); ONK-004, an orally administered agent aimed at attenuating fibrotic scarring across multiple organ systems; ONK-501, a selective apoptosis inducer in Phase I development for pancreatic adenocarcinoma; and ONK-103, a next-generation immuno-modulator advancing through IND-enabling studies. Each program is supported by biomarker-driven patient stratification strategies to optimize clinical development and therapeutic impact.

Headquartered in Cambridge, Massachusetts, OnKure maintains research facilities in North America and Europe, fostering collaborations with academic institutions, contract research organizations and strategic industry partners. The company’s global footprint enables it to conduct multi-site clinical trials and to tap into specialized expertise in fibrosis biology, oncology drug development and translational sciences.

Founded in 2015 and publicly listed following a business combination in 2023, OnKure is led by a management team with extensive experience in pharmaceutical R&D, clinical development and regulatory affairs. The senior leadership includes seasoned executives who have held senior roles at leading biotechnology and pharmaceutical companies, providing deep expertise in target validation, clinical operations and commercialization planning.

Key Stats

• Today's Range: $2.27 to $2.59
• 50-Day Range: $1.83 to $2.99
• 52-Week Range: $1.70 to $20.00
• Volume: 131,662 shs
• Average Volume: 107,045 shs
• Market Capitalization: $31.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.33
• Consensus Rating: Buy

OnKure Therapeutics Stock Analysis - MarketRank™

OnKure Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 492nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

OnKure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

OnKure Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OnKure Therapeutics are expected to grow in the coming year, from ($4.05) to ($3.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OnKure Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OnKure Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

OnKure Therapeutics has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OKUR.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OnKure Therapeutics does not currently pay a dividend.

Dividend Growth

OnKure Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for OKUR.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for OnKure Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 6 people have searched for OKUR on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.

MarketBeat Follows

3 people have added OnKure Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, OnKure Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,404,150.00 in company stock.

Percentage Held by Insiders

Only 2.30% of the stock of OnKure Therapeutics is held by insiders.

Percentage Held by Institutions

90.98% of the stock of OnKure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OKUR Stock Analysis - Frequently Asked Questions

How have OKUR shares performed this year?

OnKure Therapeutics' stock was trading at $8.60 on January 1st, 2025. Since then, OKUR stock has decreased by 72.9% and is now trading at $2.33.

How were OnKure Therapeutics' earnings last quarter?

OnKure Therapeutics, Inc. (NASDAQ:OKUR) issued its quarterly earnings data on Tuesday, May, 6th. The company reported ($1.19) EPS for the quarter, beating the consensus estimate of ($1.41) by $0.22.

How do I buy shares of OnKure Therapeutics?

Shares of OKUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/20/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OKUR
• Previous Symbol: NASDAQ:OKUR
• CIK: 1637715
• Web: reneopharma.com
• Phone: 858-283-0280
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for OnKure Therapeutics: $32.33
• High Price Target: $34.00
• Low Price Target: $30.00
• Potential Upside/Downside: +1,287.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$52.67 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -49.13%
• Return on Assets: -45.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.18
• Quick Ratio: 11.17

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.78 per share
• Price / Book: 0.30

Miscellaneous

• Outstanding Shares: 13,510,000
• Free Float: 13,199,000
• Market Cap: $31.48 million
• Optionable: N/A
• Beta: 0.41